Development of topical eye-drops of lactoferrin-loaded biodegradable nanoparticles for the treatment of anterior segment inflammatory processes

López-Machado, Ana; Diaz, N.; Cano, Amanda; Espina, Marta; Badı́a, Josefa; Baldomà, Laura; Calpena, Ana C.; Biancardi, Martina; Souto, Eliana B.; García, María L.

doi:10.1016/j.ijpharm.2021.121188

Cited by 25 publications

(23 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lico-A PLGA NPs, Lico-A PLGA-PEG-Tet-1 NPs, and Lico-A PLGA-PEG-B6 NPs were observed by TEM after negative staining (Figure 4). In all the cases, Lico-A loaded NPs showed a spherical shape and a smooth surface, characteristic of this type of drug delivery system, without any aggregation phenomena [52]. As expected, NPs size measured by TEM was similar to the size obtained by PCS [59].…”

Section: Morphology Of Licochalcone-a Functionalized Nanoparticlessupporting

confidence: 81%

“…Readings were carried out 30 min after the application of the sample, using the left eye as a negative control (n = 3/group). OII was determined as previously described elsewhere [52].…”

Section: In Vivo Ocular Tolerancementioning

confidence: 99%

“…The ability of the developed formulations to revert to ocular inflammation was demonstrated in New Zealand rabbits. Therefore, Lico-A PLGA NPs, Lico-A PLGA-PEG-Tet-1 NPs, and Lico-A PLGA-PEG-B6 NPs were evaluated in vivo in New Zealand rabbits [52].…”

Section: Anti-inflammatory Therapeutic Efficacy Of Licochalcone-a Fun...mentioning

confidence: 99%

See 2 more Smart Citations

Development of Peptide Targeted PLGA-PEGylated Nanoparticles Loading Licochalcone-A for Ocular Inflammation

et al. 2022

Self Cite

View full text Add to dashboard Cite

Licochalcone-A is a natural compound with anti-inflammatory properties. However, it possesses low water solubility, making its application for the treatment of ocular inflammation difficult. To overcome this drawback, biodegradable nanoparticles incorporating Licochalcone-A have been developed. Additionally, to avoid fast clearance and increase cellular internalization into the ocular tissues, PLGA nanoparticles have been functionalized using PEG and cell penetrating peptides (Tet-1 and B6). To optimize the formulations, a factorial design was carried out and short-term stability of the nanoparticles was studied. Moreover, morphology was also observed by transmission electron microcopy and in vitro drug release was carried out. Ocular tolerance of the formulations was ensured in vitro and in vivo and anti-inflammatory therapeutic efficacy was also assessed. Surface functionalized nanoparticles loading Licochalcone-A were developed with an average size below 200 nm, a positive surface charge, and a monodisperse population. The formulations were non-irritant and showed a prolonged Licochalcone-A release. Despite the fact that both Licochalcone-A Tet-1 and B6 functionalized nanoparticles demonstrated to be suitable for the treatment of ocular inflammation, B6 targeted nanoparticles provided greater therapeutic efficacy in in vivo assays.

show abstract

Section: Morphology Of Licochalcone-a Functionalized Nanoparticlessupporting

confidence: 81%

“…Readings were carried out 30 min after the application of the sample, using the left eye as a negative control (n = 3/group). OII was determined as previously described elsewhere [52].…”

Section: In Vivo Ocular Tolerancementioning

confidence: 99%

See 1 more Smart Citation

Development of Peptide Targeted PLGA-PEGylated Nanoparticles Loading Licochalcone-A for Ocular Inflammation

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Before one hour, no significant differences between free DXI and DXI NLC were found. This could be due to the fact that, during the first hour, the DXI that was located on the NLCs’ surface was released in a similar manner to free DXI due to a burst effect [ 43 , 44 ]. After the first hour, the DXI that was encapsulated in the inner core started being released at a slower rate than the free DXI, causing significant differences.…”

Section: Resultsmentioning

confidence: 99%

Novel Strategies against Cancer: Dexibuprofen-Loaded Nanostructured Lipid Carriers

Thiruchenthooran

Świtalska

Bonilla

et al. 2022

IJMS

Self Cite

View full text Add to dashboard Cite

The aim of this work was to design innovative nanostructured lipid carriers (NLCs) for the delivery of dexibuprofen (DXI) as an antiproliferative therapy against tumoral processes, and overcome its side effects. DXI-NLC samples were prepared with beeswax, Miglyol 812 and Tween 80 using high-pressure homogenization. A two-level factorial design 24 was applied to optimize the formulation, and physicochemical properties such as particle size, zeta potential, polydispersity index and entrapment efficiency were measured. Optimized parameters of DXI-NLCs exhibited a mean particle size of 152.3 nm, a polydispersity index below 0.2, and high DXI entrapment efficiency (higher than 99%). Moreover, DXI-NLCs provided a prolonged drug release, slower than the free DXI. DXI-NLCs were stable for 2 months and their morphology revealed that they possess a spherical shape. In vitro cytotoxicity and anticancer potential studies were performed towards prostate (PC-3) and breast (MDA-MB-468) cancer cell lines. The highest activity of DXI-NLCs was observed towards breast cancer cells, which were effectively inhibited at 3.4 μM. Therefore, DXI-NLCs constitute a promising antiproliferative therapy that has proven to be especially effective against breast cancer.

show abstract

“…Besides, hydrodynamic diameter, polydispersity index (PDI) and zeta potential of the NPs were determined at pH 7.4 in PBS by dynamic light scattering (DLS; Nano series ZEN 3600, Malvern, United Kingdom). The encapsulation efficiency (EE) and drug-loading capacity (LC) were determined indirectly by measuring the unloaded ICG@uPA in the supernatant according to previous reports ( Zhang et al, 2016 ; López-Machado et al, 2021 ). Specifically, the supernatant during centrifuge and rinsing was collected and diluted to a fixed volume, then the amount of un-loaded ICG@uPA was measured by UV-Visible spectrophotometer.…”

Section: Methodsmentioning

confidence: 99%

Cyclic RGD functionalized PLGA nanoparticles loaded with noncovalent complex of indocyanine green with urokinase for synergistic thrombolysis

Zhang

Ren

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Thrombotic diseases have the characteristics of long latency period, rapid onset, and high mortality rate, which seriously threaten people’s life and health. The aim of this research is to fabricate a novel indocyanine green complex of urokinase (ICG@uPA) and employ the amphiphilic PEG-PLGA polymer to deliver the complex as an enzyme-phototherapeutic synergistic thrombolysis platform. The noncovalent indocyanine green (ICG) complex of urokinase (ICG@uPA) was prepared via supramolecular self-assembly and then encapsulated into cRGD decorated polymeric nanoparticles (cRGD-ICG-uPA NPs) by double-emulsion solvent evaporation method. Then the nanoparticles (NPs) were characterized in terms of particle size, optical properties, in vitro release, etc. The targeting and thrombolytic effect of the nanoparticles were studied both in vitro and in vivo. ICG@uPA and cRGD-ICG-uPA NPs displayed significantly higher photostability and laser energy conversion efficiency than free ICG. Concomitantly, the NPs exhibited selective binding affinity to the activated platelets and specific accumulation in the mouse mesenteric vessel thrombus. Significant thrombolysis was achieved in vivo by photo-assisted synergistic therapy with reduced dose and systemic bleeding risk of uPA. Our results prove that the functional PLGA nanoparticle loaded with the ICG@uPA offers a novel option for effective and safe thrombolytic treatment.

show abstract

Development of topical eye-drops of lactoferrin-loaded biodegradable nanoparticles for the treatment of anterior segment inflammatory processes

Cited by 25 publications

References 74 publications

Development of Peptide Targeted PLGA-PEGylated Nanoparticles Loading Licochalcone-A for Ocular Inflammation

Development of Peptide Targeted PLGA-PEGylated Nanoparticles Loading Licochalcone-A for Ocular Inflammation

Novel Strategies against Cancer: Dexibuprofen-Loaded Nanostructured Lipid Carriers

Cyclic RGD functionalized PLGA nanoparticles loaded with noncovalent complex of indocyanine green with urokinase for synergistic thrombolysis

Contact Info

Product

Resources

About